4.8 Article

Detrimental effects of adenosine signaling in sickle cell disease

期刊

NATURE MEDICINE
卷 17, 期 1, 页码 79-U252

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nm.2280

关键词

-

资金

  1. US National Institute of Health [DK077748, DK083559, HL070952, HL092188]
  2. China National Science Foundation Scholarship Council [2008637068]
  3. NATIONAL CANCER INSTITUTE [P30CA125123] Funding Source: NIH RePORTER
  4. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL113574, R01HL070952, R01HL092188] Funding Source: NIH RePORTER
  5. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211] Funding Source: NIH RePORTER
  6. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK077748, R01DK083559] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Hypoxia can act as an initial trigger to induce erythrocyte sickling and eventual end organ damage in sickle cell disease (SCD). Many factors and metabolites are altered in response to hypoxia and may contribute to the pathogenesis of the disease. Using metabolomic profiling, we found that the steady-state concentration of adenosine in the blood was elevated in a transgenic mouse model of SCD. Adenosine concentrations were similarly elevated in the blood of humans with SCD. Increased adenosine levels promoted sickling, hemolysis and damage to multiple tissues in SCD transgenic mice and promoted sickling of human erythrocytes. Using biochemical, genetic and pharmacological approaches, we showed that adenosine A(2B) receptor (A(2B)R)-mediated induction of 2,3-diphosphoglycerate, an erythrocyte-specific metabolite that decreases the oxygen binding affinity of hemoglobin, underlies the induction of erythrocyte sickling by excess adenosine both in cultured human red blood cells and in SCD transgenic mice. Thus, excessive adenosine signaling through the A(2B)R has a pathological role in SCD. These findings may provide new therapeutic possibilities for this disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据